Malmö, Sweden

Niklas Landberg

This inventor holds 1 USPTO granted patent. Top assignee: Lead Biologics International Ab. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Niklas Landberg. Retrieved from https://idiyas.com/inventor/niklas-landberg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Niklas Landberg: Inventor in Hematologic Disease Research

Introduction

Niklas Landberg is an inventor based in Malmö, Sweden. His patent work concerns agents that target SLAMF6, a protein relevant to pathological cells and immune-cell interactions in neoplastic hematologic disorders. Landberg is associated with Lead Biologics International AB.

Latest Patents

Landberg is named on one patent, 1 patent, titled “Agents and Uses Thereof.” The invention describes agents with binding specificity for Signaling Lymphocytic Activating Molecule Family Member 6 (SLAMF6). These agents are intended to induce cell death or inhibit the growth and proliferation of pathological stem cells and progenitor cells associated with neoplastic hematologic disorders when those cells express SLAMF6. The patent also describes using the agents to modulate interactions between such cells and immune cells, and to detect SLAMF6-expressing pathological stem cells, progenitor cells, or immune cells. It further covers related pharmacological compositions and methods of use.

Career Highlights

The available information identifies Landberg’s patent activity in the field of targeted agents for hematologic disorders. His work focuses on SLAMF6 as a potential target for detecting and affecting disease-associated cells.

Collaborations

Landberg’s listed coworkers include Thoas Fioretos and Carl Sandén. The patent information connects his work with Lead Biologics International AB.

Conclusion

Niklas Landberg’s documented invention explores SLAMF6-targeting agents for detecting and addressing pathological cells associated with neoplastic hematologic disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…